AbbVie
ABBV
$151.01
Share price
-0.47%
Change (1 day)
28.95%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Market capitalization of AbbVie (ABBV)
Market cap: $266.85 Billion
As of May 2022 AbbVie has a market cap of $266.85 Billion. This makes AbbVie the world's 30th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to mesure how much a company is worth.
Market cap history of AbbVie from 2012 to 2022
| Year | Market cap | Change |
|---|---|---|
| 2022 | $266.85 B | 11.48% |
| 2021 | $239.37 B | 26.54% |
| 2020 | $189.17 B | 44.47% |
| 2019 | $130.94 B | -3.95% |
| 2018 | $136.33 B | -11.7% |
| 2017 | $154.39 B | 51.71% |
| 2016 | $101.76 B | 6.7% |
| 2015 | $95.37 B | -8.42% |
| 2014 | $104.14 B | 24.23% |
| 2013 | $83.82 B | 55.32% |
| 2012 | $53.97 B |
End of Day market cap according to different sources
On May 20th, 2022 the market cap of AbbVie was reported to be:
$266.85 Billion
$266.85 Billion
$266.85 Billion
$266.85 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $294.40 B | 10.33% | 🇺🇸 USA |
 Eli Lilly LLY | $283.95 B | 6.41% | 🇺🇸 USA |
 Amgen AMGN | $132.21 B | -50.45% | 🇺🇸 USA |
 Biogen BIIB | $29.23 B | -89.04% | 🇺🇸 USA |
 Gilead Sciences GILD | $80.07 B | -69.99% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $162.21 B | -39.21% | 🇺🇸 USA |
 Astrazeneca AZN | $205.18 B | -23.11% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $114.83 B | -56.97% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $8.23 B | -96.91% | 🇺🇸 USA |